EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Nano‐Interception Strategy for Chronic Heart Failure: Prussian Blue Nanoparticles Disrupt Fibroblast‐Immune Communication via CCL2 Sequestration

Bo Chen, Gao Wei, Guowei Zeng, Haoyu Li, Rongrong Wu, Hongyu Yan, Zijie Zhou, Kai Luo, Xiaoyang Zhang, Cong Li, Longming Huang, Lingyan Cheng und 5 weitere

Advanced Materials · 2026-06 · 38 (31)

DOI: 10.1002/adma.202520209 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 24.04.2026. Verfasst von Bo Chen und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiothoracic Surgery, Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, P.…. Hauptthemen laut MEDLINE: Heart Failure, Ferrocyanides, Nanoparticles, Fibroblasts. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities, Natural Foundation of Shanghai Science and Technology Committee.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic heart failure (HF) remains a global health challenge due to the lack of therapies that effectively disrupt the pathological fibro‐inflammatory networks driving disease progression. While current nanomedicine strategies often target intracellular pathways in isolated cell types, they overlook the multicellular crosstalk central to HF. Here, we develop scalably synthesized Prussian blue (PB) nanoparticles that selectively intercept the CCL2‐CCR2 chemokine axis, a key pathway in fibroblast‐macrophage communication. Single‐nucleus RNA sequencing of murine and human failing hearts identifies a conserved pro‐fibroinflammatory cardiac fibroblast subpopulation (POSTN hi CCL2 hi ) that recruits CCR2 + macrophages via CCL2 secretion. PB nanoparticles exhibit ultrahigh affinity (K D = 1.11 × 10 −10 m ) for free CCL2, inducing conformational distortion in its N‐terminal domain via specific C≡N interface interactions with CRS1 residues, thereby blocking CCR2 engagement, a mechanism distinct from conventional nanomaterials. Although ineffective in monocultures, PB nanoparticles robustly improve cardiac function and remodeling in murine and translational porcine pressure‐overload HF models, reducing left ventricular end‐diastolic volume by 56.2% and fibrosis by 40.5%, while selectively depleting CCR2 + macrophages without systemic immunosuppression. Supported by scalable production (> 100 g/batch), long‐term stability, and biosafety, this work establishes a cell communication‐targeting nanomedicine strategy for network‐driven diseases like HF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureFerrocyanidesNanoparticlesFibroblastsChemokine CCL2Cell CommunicationAnimalsMiceHumansMacrophagesChronic DiseaseReceptors, CCR2SwineNanomedicine

Stichwörter der Autor:innen

Prussian blue nanoparticlefibroblast‐immune communicationheart failurenanomedicine

Substanzen

ferric ferrocyanideFerrocyanidesChemokine CCL2Receptors, CCR2

Autor:innen und Institutionen

  • Department of Cardiothoracic Surgery, Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.
  • Department of Ultrasound in Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.
  • Heart Center and Shanghai Institute of Pediatric Congenital Heart Disease, Shanghai Children's Medical Center, National Children's Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai, P. R. China.

ORCID-Profile: Xiaojun Cai

Förderung

  • National Natural Science Foundation of China
  • Fundamental Research Funds for the Central Universities
  • Natural Foundation of Shanghai Science and Technology Committee
  • Shanghai Jiao Tong University School of Medicine's "Clinical Professional Research Team" Project
  • Shanghai Key Research Center Construction Project-Shanghai Research Center for Pediatric Cardiovascular Diseases
  • National Clinical Key Specialty Construction Project

Zitieren

APA

Chen, B., Wei, G., Zeng, G., Li, H., Wu, R., Yan, H., Zhou, Z., Luo, K., Zhang, X., Li, C., Huang, L., Cheng, L., Zhang, X., Zheng, J., Shi, B., Cai, X., & He, X. (2026). A Nano‐Interception Strategy for Chronic Heart Failure: Prussian Blue Nanoparticles Disrupt Fibroblast‐Immune Communication via CCL2 Sequestration. Advanced Materials, 38(31). https://doi.org/10.1002/adma.202520209

Vancouver

Chen B, Wei G, Zeng G, Li H, Wu R, Yan H, et al. A Nano‐Interception Strategy for Chronic Heart Failure: Prussian Blue Nanoparticles Disrupt Fibroblast‐Immune Communication via CCL2 Sequestration. Advanced Materials. 2026;38(31). doi:10.1002/adma.202520209

BibTeX
@article{Chen2026,
  author = {Chen, Bo and Wei, Gao and Zeng, Guowei and Li, Haoyu and Wu, Rongrong and Yan, Hongyu and Zhou, Zijie and Luo, Kai and Zhang, Xiaoyang and Li, Cong and Huang, Longming and Cheng, Lingyan and Zhang, Xinjie and Zheng, Jinghao and Shi, Bozhong and Cai, Xiaojun and He, Xiaomin},
  title = {A Nano‐Interception Strategy for Chronic Heart Failure: Prussian Blue Nanoparticles Disrupt Fibroblast‐Immune Communication via CCL2 Sequestration},
  journal = {Advanced Materials},
  year = {2026},
  volume = {38},
  number = {31},
  doi = {10.1002/adma.202520209}
}
Kostenlos starten →